Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...

UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...

StimLabs®, a leading regenerative medicine company, announces the launch of Allacor P, the first medical device derived from human umbilical cord extracellular matrix (ECM). Allacor P was awarded an A ...

New human clinical trial proves arginine, an amino acid, can modify plaque formation on teeth, thereby protecting ...

UK-based biotechnology company Engitix Ltd. has raised a further $25 million from billionaire Michael Platt to help develop its therapies for cancer and fibrosis.

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together ...

Detecting cancer in the earliest stages could dramatically reduce cancer deaths because cancers are usually easier to treat ...

TYBR Health has announced the first US clinical use of the collagen-based tissue protector, B3 GEL System, aimed at ...

StimLabs has announced the launch of Allacor P, a human umbilical cord device designed for acute and chronic wound management ...

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.

Structural alignment in fibrous tissues like myocardium and tendons is a key biomarker of physiological integrity and ...